🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine nejm.org/doi/full/10.10…

1/ The "this shoulda been an oral" #MMsm poster of #Tandem25 - worth reviewing if you use cilta-cel! Rapid or sustained ALC ⬆️⬆️ appear to drive tox with BCMA CAR-T. CBCI now starting dex preemptively if ALC > 5.0 even if no tox yet - well-powered RCT hopefully coming soon!

Our paper on establishing targeted therapy for MM with 1q+ is online ahead of print in @BloodJournal! w/ Liz Lightbody, Mairead Reidy, Irene Ghobrial Gaddy Getz & Salomon Manier! ashpublications.org/blood/article-…

#Myeloma Paper of the Day: Clonal hematopoiesis frequently co-exists w/ myeloma @ dx, associates w/ more advanced stage, age, decreased naïve T cells, a pro-inflammatory TME, decreased DC antigen-presenting fxn & exhaustion markers in CD8 cells: pubmed.ncbi.nlm.nih.gov/40112284/. #mmsm

Are you joining us tomorrow for iwGPRC5d? ⁦Ross Firestone⁩ ⁦Tomas Jelinek⁩ ⁦Andrew Yee, MD⁩ ⁦Rahul Banerjee, MD, FACP⁩ #mmsm iwgprc5d.org/agenda/

Beautiful work presented at ⁦Myeloma Society⁩ workshop by ⁦Dr. @Samir Parekh ⁦Icahn School of Medicine at Mount Sinai⁩ on the involvement of S100A8/9 (alarmins) in the MDSC-mediated immune suppression post CARTs and bispecifics and potential for S100A8/9 neutralizing antibodies #mmsm

#Myeloma Paper of the Day: Flatiron health record analysis comparing carfilzomib dosing in relapsed/refractory myeloma finds no support for improved outcomes w/ 2x weekly dosing; K56-1x may best balance efficacy, safety & avoidance of time toxicity: pubmed.ncbi.nlm.nih.gov/40155649/. #mmsm

Samir Parekh is named Director of Center of Excellence for Multiple Myeloma mountsinai.org/about/newsroom… Icahn School of Medicine at Mount Sinai #multiplemyeloma

#Myeloma Paper of the Day: Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in myeloma includes higher risk of prolonged transfusion dependence for both pRBC and G-CSF us, as well as higher thrombopoietin receptor agonist use: pubmed.ncbi.nlm.nih.gov/40203191/. #mmsm

Thank you OncoDaily for taking an interest in my journey and sharing my story.

Practice-Changing Studies in Multiple Myeloma With Samir Parekh, MBBS bloodcancerstoday.com/post/practice-… #MultipleMyeloma Icahn School of Medicine at Mount Sinai

Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in #MultipleMyeloma rdcu.be/ekW4D Darren Pan @Tarekmd91 Santiago Thibaud, MD Shambavi Richard Joshua Richter, MD, FACP Hearn Jay Cho MD, PhD Cesar Rodriguez, MD (Myelomatips.com) Icahn School of Medicine at Mount Sinai

#Myeloma Paper of the Day: Multiomic analysis of #Waldenström macroglobulinemia finds two disease subtypes, including memory B-cell-like (MBC-like) & plasma cell-like (PC-like) w/ distinct epigenetic, mutational, transcriptional & clinical features: pubmed.ncbi.nlm.nih.gov/40332467/. #mmsm

1/ 🧵Check out our new study in Nature Genetics, which examines how precancerous conditions (MGUS/SMM) evolve into Multiple Myeloma, and offers new computational methods to predict progression risk and model cancer evolution. doi.org/10.1038/s41588…

Outstanding cilta-cel results and even more amazing is that I get to see some of those myeloma patients who are potentially “cured” in clinic at Mount Sinai! #mmsm The Tisch Cancer Institute

#Myeloma Paper of the Day: MIDAS study of MRD-guided consolidation strategy in pts eligible for ASCT finds those who were MRD-negative @ 10-5 post-induction % w/ pre-maintenance MRD- status at 10-6 sensitivity was not higher with ASCT vs. Isa-KRd: pubmed.ncbi.nlm.nih.gov/40459097/. #mmsm

people.com/jonathan-gluck… Hearn Jay Cho MD, PhD discusses advancements in treating #MultipleMyeloma Icahn School of Medicine at Mount Sinai Multiple Myeloma RF

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

Happy to share our new work out today on Blood Journals Portfolio #Blood where we report CD38 loss as recurrent mechanisms of resistance to anti-CD38 antibody in multiple myeloma. Great collaboration between Memorial Sloan Kettering Cancer Center MSK Department of Medicine U Calgary Heidelberg Myeloma Mayo Clinic #mmsm #wgs

#Myeloma Paper of the Day: Biallelic antigen escape may be mechanism of resistance to anti-CD38 antibodies; L153H & C275Y decreased binding affinity & ADCC of daratumumab & isatuximab while a 3rd, R140G, conferred selective resistance to dara only: pubmed.ncbi.nlm.nih.gov/40493883/. #mmsm